INMED Pharmaceuticals Advances Pipeline Amid Financial Losses
By ATTN Desk · Editorial oversight: Sean Han
INMED PHARMACEUTICALS INC (INM)
1. Introduction
INMED PHARMACEUTICALS INC (NASDAQ: INM) is a clinical-stage pharmaceutical company developing proprietary small-molecule drug candidates targeting the CB1 and CB2 receptors. Its pipeline includes three programs addressing Alzheimer’s disease, age-related macular degeneration (AMD), and epidermolysis bullosa (EB). Through its subsidiary BayMedica, the company manufactures high-purity, non-intoxicating rare cannabinoids for the health and wellness industry.
Stock Data (June 2, 2025)
- Price: $5.89 (+136.55%)
- Volume: 10,625,388
- Exchange: NASDAQ
- 52-Week Range: $1.72 – $15.70
2. Corporate Structure
- Headquarters: Vancouver, British Columbia
- Employee Count: 11–50 (LinkedIn)
- Key Executives:
- Eric A. Adams, President & CEO (since 2016)
- Michael Woudenberg, COO
- Netta Jagpal, CPA, CFO
- Eric C. Hsu, Ph.D., SVP Pre-Clinical R&D
3. Recent Developments and News
- April 2024
- Preclinical studies for INM-089 (AMD candidate) demonstrated neuroprotection of photoreceptors and improvements in retinal pigment epithelium integrity.
- Preclinical studies of INM-901 (Alzheimer’s candidate) showed potential neuroprotective effects and reduction of neuroinflammation in established disease models.
- Phase 2 Clinical Trial (EB)
- INM-755 topical cream completed a Phase 2 trial for epidermolysis bullosa, indicating enhanced anti-itch activity compared to a control treatment.
- May 13, 2025 (Form 8-K)
- Fiscal Q3 2025 results indicated an increase in net loss due to higher R&D expenses; BayMedica's commercial revenues increased by 8%.
- May 29, 2025 (DEFA14A Proxy)
- A proposal to issue up to 20% of outstanding shares under a Standby Equity Purchase Agreement (SEPA); a special shareholder meeting is scheduled for June 13, 2025.
4. Financial and Strategic Analysis
Key Financial Metrics (TTM / Most Recent)
| Metric | Value |
|---|---|
| Market Cap (intraday) | $3.006 M |
| Revenue | $4.92 M |
| Net Income | -$8.31 M |
| EPS | -11.65 |
| Profit Margin | -168.90% |
| Cash (MRQ) | $4.72 M |
| Debt/Equity (MRQ) | 12.09% |
| Price/Sales | 0.36 |
| Price/Book | 0.42 |
- Capital Strategy: The SEPA proposal aims to enhance liquidity; shareholder approval is required by June 13, 2025.
- R&D Focus: Advances in three pipeline programs, with INM-755 seeking partnerships for further development.
- Revenue Generation: BayMedica supplies rare cannabinoids (CBC, Δ⁹-THCV, CBDV, CBTC) to B2B customers, contributing to cash flow.
5. Market Position and Industry Context
- Pipeline Differentiation: Proprietary cannabinoid analogs that are patentable and recognized as new chemical entities (NCEs) compared to natural plant-derived cannabinoids.
- Industry Growth Projections:
- Global cannabinoid-derived pharmaceuticals market:
– Valued at $636.8 M in 2021; projected to reach $11.24 B by 2030, with a CAGR of 37.7% (InsightAce Analytic). - U.S. minor cannabinoids market:
– Estimated at $11.5 B in 2023; expected CAGR of 15.0% from 2024 to 2030 (Grandview Research).
- Global cannabinoid-derived pharmaceuticals market:
- Competitive Landscape: The market includes companies focused on cannabinoid-based therapeutics and rare cannabinoid manufacturing; INMED's integrated R&D and manufacturing model through BayMedica supports both drug development and ingredient supply.
tl;dr
- June 2, 2025: INM closed at $5.89, up 136.55%.
- June 13, 2025: Special meeting to vote on SEPA allowing the issuance of up to 20% new shares for capital.
- Q3 2025 results (May 13, 2025): net loss rose; BayMedica revenues increased by 8%.
- Pipeline milestones: INM-089 (AMD) and INM-901 (Alzheimer’s) in preclinical studies; INM-755 (EB) completed Phase 2.
- Funding outlook relies on shareholder approval of the SEPA and potential clinical data readouts.